NCT07191730View on ClinicalTrials.gov

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Not yet recruitingOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2028

Conditions

CardiotoxicityHeart FailureNeoplasmsBreast Neoplasms

All Listed Sponsors

lead

University Hospital, Caen

OTHER

NCT07191730 - ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies | Biotech Hunter | Biotech Hunter